A novel recombinant soluble splice variant of met is a potent antagonist of the hepatocyte growth factor/scatter factor-met pathway

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4612-4621

  Tiran, Zohar ^a   Oren, Anat ^a   Hermesh, Chen ^a   Rotman, Galit ^a   Levine, Zurit ^a   Amitai, Hagit ^a   Handelsman, Tal ^a   Beiman, Merav ^a   Chen, Aviva ^a   Landesman Milo, Dalit ^a   Dassa, Liat ^a   Peres, Yair ^a   Koifman, Cynthia ^a   Glezer, Sarit ^a   Vidal Finkelstein, Rinat ^a   Bahat, Kobi ^a   Pergam, Tania ^a   Israel, Cylia ^a   Horev, Judith ^b   Tsarfaty, Ilan ^b   Ayalon Soffer, Michal ^a   more..

^a Compugen Ltd ^*

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE RECEPTOR ANTAGONIST; PROTEIN CGEN 241A; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE; ISOPROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; RNA SPLICING; ANIMAL; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 51649111766     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0108     Document Type: Article

References (50)

1. Birchmeier C, Birchmeier W, Gherardi E. Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
2. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006;20:1611-21.
3. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225: 1-26.
4. Gao CF. Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Res 2005;15:49-51.
5. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003;22:309-25.
6. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12: 3657-60.
7. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13:41-59.
8. Laufs S, Schumacher J, Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006; 5:1760-71.
9. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
10. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92.
11. Zhang YW, Vande Woude GF. HGF/SF-Met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17.
12. Choong NW, Ma PC, Salgia R. Therapeutic targeting of receptor tyrosine kinases in lung cancer. Expert Opin Ther Targets 2005;9:533-59.
13. Jiang WG, Martin TA, Parr C, Davies G, Matsumoto K, Nakamura T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005;53:35-69.
14. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007;9:102-8.
15. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006;66:1721-9.
16. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98:7443-8.
17. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8.
18. Jiao Y, Zhao P, Zhu J, et al. Construction of human naive Fab library and characterization of anti-Met Fab fragment generated from the library. Mol Biotechnol 2005;31:41-54.
19. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52.
20. Matsumoto K, Nakamura T. Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 2005;333:316-27.
21. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
22. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11: 2312-9.
23. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002;21:4885-93.
24. Firon M, Shaharabany M, Altstock RT, et al. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 2000;19:2386-97.
25. Shoshan A, Grebinskiy V, Magen A, et al. Designing oligo libraries taking alternative splicing into account. In: Proceedings of SPIE; 2001. p. 86-95.
26. Sorek R, Ast G, Graur D. Alu-containing exons are alternatively spliced. Genome Res 2002;12:1060-7.
27. Sorek R, Safer HM. A novel algorithm for computational identification of contaminated EST libraries. Nucleic Acids Res 2003;31:1067-74.
28. Xie H, Zhu WY, Wasserman A, Grebinskiy V, Olson A, Mintz L. Computational analysis of alternative splicing using EST tissue information. Genomics 2002;80:326-30.
29. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987;47:3239-45.
30. Rong S, Oskarsson M, Faletto D, et al. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human Met protooncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ 1993;4:563-9.
31. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000;60:342-9.
32. Hiscox S, Parr C, Nakamura T, Matsumoto K, Mansel RE, Jiang WG. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. Breast Cancer Res Treat 2000;59: 245-54.
33. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 2001;84: 864-73.
34. Martin TA, Parr C, Davies G, et al. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003;24:1317-23.
35. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-7.
36. Parr C, Hiscox S, Nakamura T, Matsumoto K, Jiang WG. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells. Int J Cancer 2000; 85:563-70.
37. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103: 2316-21.
38. Shinomiya N, Gao CF, Xie Q, et al. RNA interference reveals that ligand-independent Met activity is required for tumor cell signaling and survival. Cancer Res 2004;64:7962-70.
39. Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. Clin Cancer Res 2007;13:2191-8.
40. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
41. Brockmann MA, Papadimitriou A, Brandt M, Fillbrandt R, Westphal M, Lamszus K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin Cancer Res 2003;9:4578-85.
42. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 2006;103: 5090-5.
43. Wickramasinghe D, Kong-Beltran M. Met activation and receptor dimerization in cancer: a role for the Sema domain. Cell Cycle 2005;4:683-5.
44. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell 2004;6: 75-84.
45. Zhang YW, Graveel C, Shinomiya N, Vande Woude GF. Met decoys: will cancer take the bait? Cancer Cell 2004;6:5-6.
46. Michieli P, Mazzone M, Basilico C, et al. Targeting the tumor and its microenvironment by a dualfunction decoy Met receptor. Cancer Cell 2004;6: 61-73.
47. Lin JC, Naujokas M, Zhu H, Nolet S, Park M. Intronexon structure of the MET gene and cloning of an alternatively-spliced Met isoform reveals frequent exon-skipping of a single large internal exon. Oncogene 1998;16:833-42.
48. Rodrigues GA, Park M. Isoforms of the Met receptor tyrosine kinase. Exs 1993;65:167-79.
49. Rodrigues GA, Naujokas MA, Park M. Alternative splicing generates isoforms of the Met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 1991;11:2962-70.
50. Levine SJ. Mechanisms of soluble cytokine receptor generation. J Immunol 2004;173:5343-8.